Cutler Investment Counsel’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.4M Buy
87,765
+134
+0.2% +$15.7K 1.07% 30
2026
Q1
$10.6M Sell
87,631
-949
-1% -$110K 1.09% 31
2025
Q4
$9.4M Sell
88,580
-3,421
-4% -$321K 0.98% 34
2025
Q3
$7.79M Sell
92,001
-1,004
-1% -$82.7K 0.82% 44
2025
Q2
$7.44M Sell
93,005
-305
-0.3% -$24.2K 0.83% 44
2025
Q1
$8.45M Sell
93,310
-3,765
-4% -$352K 1.02% 37
2024
Q4
$9.73M Sell
97,075
-2,002
-2% -$206K 1.21% 34
2024
Q3
$11.3M Sell
99,077
-3,127
-3% -$372K 1.43% 26
2024
Q2
$12.7M Sell
102,204
-734
-0.7% -$94.5K 1.73% 22
2024
Q1
$13.7M Sell
102,938
-554
-0.5% -$68.3K 1.83% 20
2023
Q4
$11.4M Buy
103,492
+3,181
+3% +$330K 1.62% 24
2023
Q3
$10.4M Sell
100,311
-1,201
-1% -$129K 1.64% 25
2023
Q2
$11.8M Sell
101,512
-4,257
-4% -$483K 1.78% 24
2023
Q1
$11.3M Buy
105,769
+499
+0.5% +$53.9K 1.76% 23
2022
Q4
$11.8M Sell
105,270
-3,976
-4% -$406K 1.79% 22
2022
Q3
$9.48M Sell
109,246
-82
-0.1% -$7.32K 1.58% 27
2022
Q2
$10M Buy
109,328
+1,287
+1% +$114K 1.58% 27
2022
Q1
$8.87M Buy
108,041
+3,159
+3% +$249K 1.23% 32
2021
Q4
$8.04M Buy
104,882
+1,153
+1% +$91.8K 1.21% 36
2021
Q3
$7.79M Buy
103,729
+71
+0.1% +$5.4K 1.23% 34
2021
Q2
$8.06M Sell
103,658
-4,567
-4% -$340K 1.26% 33
2021
Q1
$7.96M Buy
108,225
+551
+0.5% +$40.6K 1.38% 33
2020
Q4
$8.4M Sell
107,674
-100
-0.1% -$7.65K 1.54% 26
2020
Q3
$8.53M Buy
107,774
+118
+0.1% +$9.24K 1.65% 25
2020
Q2
$7.94M Sell
107,656
-1,786
-2% -$134K 1.69% 25
2020
Q1
$8.04M Sell
109,442
-788
-0.7% -$61.9K 1.94% 23
2019
Q4
$9.57M Sell
110,230
-16,295
-13% -$1.34M 1.91% 20
2019
Q3
$10.2M Sell
126,525
-642
-0.5% -$51.5K 1.96% 21
2019
Q2
$10.2M Sell
127,167
-202
-0.2% -$15.5K 1.95% 20
2019
Q1
$10.1M Buy
127,369
+404
+0.3% +$30.2K 1.98% 22
2018
Q4
$9.26M Sell
126,965
-2,769
-2% -$195K 1.99% 22
2018
Q3
$8.78M Buy
129,734
+1,034
+0.8% +$65.9K 1.64% 28
2018
Q2
$7.45M Sell
128,700
-1,724
-1% -$97.3K 1.47% 30
2018
Q1
$6.78M Buy
130,424
+197
+0.2% +$10.6K 1.32% 39
2017
Q4
$6.99M Buy
130,227
+1,173
+0.9% +$65K 1.35% 38
2017
Q3
$7.88M Buy
129,054
+2,203
+2% +$134K 1.84% 28
2017
Q2
$7.76M Buy
126,851
+1,607
+1% +$97.8K 1.94% 27
2017
Q1
$7.59M Buy
125,244
+14,504
+13% +$880K 1.77% 27
2016
Q4
$6.22M Buy
110,740
+239
+0.2% +$14K 1.6% 33
2016
Q3
$6.58M Buy
110,501
+914
+0.8% +$53.4K 1.78% 27
2016
Q2
$6.02M Buy
109,587
+5,022
+5% +$267K 1.68% 29
2016
Q1
$5.28M Sell
104,565
-4,807
-4% -$235K 1.62% 30
2015
Q4
$5.51M Sell
109,372
-221
-0.2% -$11.1K 1.88% 29
2015
Q3
$5.17M Buy
109,593
+51
+0% +$2.71K 1.85% 29
2015
Q2
$5.95M Buy
109,542
+258
+0.2% +$14.5K 1.94% 23
2015
Q1
$5.99M Buy
109,284
+2,919
+3% +$165K 1.93% 23
2014
Q4
$5.76M Sell
106,365
-522
-0.5% -$29.1K 1.9% 28
2014
Q3
$6.05M Sell
106,887
-541
-0.5% -$30.4K 2.06% 18
2014
Q2
$5.93M Buy
107,428
+785
+0.7% +$42.8K 2.01% 21
2014
Q1
$5.78M Buy
106,643
+1,091
+1% +$56.5K 2.04% 20
2013
Q4
$5.04M Sell
105,552
-352
-0.3% -$16.1K 1.83% 28
2013
Q3
$4.81M Sell
105,904
-50
-0% -$2.28K 1.88% 26
2013
Q2
$4.7M Buy
+105,954
New +$4.73M 1.92% 29

Other funds holding MRK

Cutler Investment Counsel's MRK Position: Q2 2026 in Review

Cutler Investment Counsel increased its Merck (MRK) stake by 0.15% in Q2 2026, buying an estimated $15.7K and bringing the position to 87,765 shares worth $11.4M. The position accounts for 1.07% of the portfolio, ranked #30.

Cutler Investment Counsel first reported a position in MRK in Q2 2013 and has held it in 53 quarters since. The position peaked at $13.7M in Q1 2024. 1,549 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Cutler Investment Counsel held 87,765 shares of Merck worth $11.4M as of Q2 2026.
  • Cutler Investment Counsel bought 134 Merck shares in Q2 2026, an estimated $15.7K.
  • Merck made up 1.07% of Cutler Investment Counsel's portfolio in Q2 2026, its #30 holding.
  • Cutler Investment Counsel first reported a position in Merck in Q2 2013 and has held it in 53 quarters since.
  • Cutler Investment Counsel's Merck position peaked at $13.7M in Q1 2024.
  • 1,549 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Cutler Investment Counsel's 13F filing for Q2 2026, filed 14 Jul 2026.